Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15419135 | 0.92 | CYP11B2 (0.46) | CYP11B2CYP11B1 | |
| SCHEMBL15419133 | 0.92 | CYP11B2 (0.46) | CYP11B2CYP11B1 | |
| SCHEMBL3478622 | 0.88 | CYP11B2 (0.44) | CYP11B2CYP11B1 | |
| SCHEMBL753993 | 0.88 | CYP11B2 (0.44) | CYP11B2CYP11B1 | |
| SCHEMBL3740351 | 0.88 | CYP11B2 (0.44) | CYP11B2CYP11B1 | |
| SCHEMBL3746927 | 0.86 | CYP11B2 (0.51) | CYP11B2CYP11B1KDM1AGRIA2 | |
| SCHEMBL3751097 | 0.83 | CYP11B2 (0.47) | CYP11B2CYP11B1GRIA2 | |
| SCHEMBL751918 | 0.82 | CYP11B2 (0.55) | CYP11B2CYP11B1 | |
| SCHEMBL3746571 | 0.82 | CYP11B2 (0.55) | CYP11B2CYP11B1 | |
| SCHEMBL751919 | 0.82 | CYP11B2 (0.55) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2429995-B1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | claimed |
| US-8383827-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-02-26 | — | — | US | claimed |
| EP-2429995-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | claimed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | claimed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | claimed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| US-8809545-B2 | Aryl pyridine as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2014-08-19 | — | — | US | disclosed |
| EP-2429995-B1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| EP-2429995-B1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CHAMOIN SYLVIE (FR) | 2013-11-07 | — | — | US | disclosed |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CHAMOIN SYLVIE (FR) | 2013-11-07 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| EP-2429995-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | Novartis AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130796-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035354-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885PDK1 731/4885 |
| US-20130296309-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885PDK1 731/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | CYP11B2 610/4885CYP11B1 587/4885PDK1 4306/4885 |
| US-20100292225-A1 | ARYL PYRIDINE AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | CYP11B2 4/4885CYP11B1 2/4885PDK1 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.